Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07398950 · ClinicalTrials.gov registry record
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A clinical trial, sponsored by Yale University.
- Not yet
- Registry status
- 150
- Enrollment target
NCT07398950 is a clinical trial that has not yet begun recruiting, run by Yale University. The registered enrollment target is 150 participants.
The verdict
NCT07398950 has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- 150 participants
- Enrollment target
Study Summary
The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through comparison with technetium-99m pyrophosphate (PYP) imaging results.
Interventions
- DIAGNOSTIC_TEST ATTR-CM AI-ECG and AI-Echo Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07398950
The ClinicalTrials.gov registry entry for NCT07398950 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATTR-CM AI-ECG and AI-Echo Model is the first listed.
NCT07398950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07398950 about?
NCT07398950 is a clinical study titled "Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)". The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through...
What is the current status of trial NCT07398950?
This trial is currently not yet recruiting. The enrollment target is 150 participants. The study started on 2026-03. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07398950?
The interventions under investigation include: ATTR-CM AI-ECG and AI-Echo Model (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07398950?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.